Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed a 14% revenue decline and flat exoskeleton sales, despite increased unit sales. Gross profit improved, but operating expenses and losses remain high. The Q&A section highlighted uncertainties in the company's market strategy and competitive advantage. Positive elements included narrowed net loss and reduced operating cash usage. However, weak financial performance and lack of clear competitive strategy outweigh these positives, leading to a negative sentiment.
Key Financial Performance
Revenue for the year ended December 31, 2025 $22 million compared to $25.7 million in 2024, a decrease of approximately 14%. The decline was attributed to lower international sales and timing factors related to distributor orders.
Revenue from the sales of ReWalk personal exoskeleton $8.5 million in 2025 compared to $8.9 million in 2024, relatively flat. However, the number of units sold increased by 22% year-over-year, driven by growing adoption and increased reimbursement demand.
Revenue of the MyoCycle FES Declined by 50% to $600,000, primarily due to the transition away from an exclusive distribution arrangement and strategic focus on core products.
Revenue from the sales of AlterG products and services $12.9 million, a decline of 18% from 2024. This was primarily due to lower international sales and timing factors related to distributor orders.
Gross profit Increased to $8.4 million or 38.2% of revenue in 2025 compared to $8.2 million or 32% of revenue in 2024. The improvement was due to better cost management despite lower sales volume.
Operating expenses Declined by 25% to $28.1 million in 2025 compared to $37.6 million in 2024. This was primarily due to lower impairment charges and improved productivity in marketing and sales operations.
Operating loss Narrowed by 33% to $19.7 million in 2025 compared to $29.3 million in 2024. This was primarily due to lower impairment charges.
Net loss Narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024. This was driven by improved cost management and lower operating expenses.
Operating cash usage Reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024. The improvement was due to better working capital management, including stronger receivable collections and lower inventory levels.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ORMP-0801 Oral Insulin: Advanced clinical-stage oral insulin candidate with potential to improve glucose regulation, reduce weight gain, and lower hypoglycemia risk. New U.S. study planned.
Powered Upper Extremity Orthotic System: Acquired technology from Skelable to develop AI-powered orthotic system for stroke survivors, enabling daily activities and therapeutic goals.
Reimbursement Expansion: Achieved reimbursement for ReWalk in three largest U.S. Medicare Advantage insurers, covering over 16 million lives. Expanded international distribution to Mexico, Thailand, and UAE.
Germany as Test Market: Accelerated efforts in Europe with Germany as a primary test market for reimbursement and clinical adoption insights.
Sales and Distribution Restructuring: Transitioned to a hybrid sales model combining direct sales and external partnerships. Focused on three areas: direct-to-patient, capital equipment sales, and payer engagement.
Cost Management: Reduced operating expenses by 25% in 2025, improved marketing and sales productivity, and better working capital management.
Oramed Partnership: Strategic agreement with Oramed provides capital support and access to ORMP-0801, enhancing financial foundation and strategic scope.
Skelable Acquisition: Acquired IP and technology for upper body exoskeleton, integrating it into Lifeward's neuro rehab portfolio with the original engineering team.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue decline: Revenue for the year ended December 31, 2025, decreased by approximately 14% compared to 2024, primarily due to lower international sales and timing factors related to distributor orders.
Sales and distribution challenges: The transition to a hybrid sales and distribution model in the U.S. caused delays in revenue realization as partnerships take time to build and mature.
Distributor purchasing dynamics: A specific distributor made a large inventory purchase in 2024 but did not place a comparable order in 2025, creating a year-over-year revenue headwind.
Product-specific revenue decline: Revenue from the MyoCycle FES declined by 50%, reflecting the transition away from an exclusive distribution arrangement and strategic focus on core products.
Operating losses: Despite narrowing, the company still reported an operating loss of $19.7 million in 2025, indicating ongoing financial challenges.
R&D investment needs: While operating expenses declined, the company plans to increase R&D spending in 2026, which could strain financial resources.
Reimbursement dependency: The company’s growth strategy heavily relies on expanding reimbursement coverage, which is a critical but uncertain factor.
International market risks: Efforts to expand into international markets, such as Europe and emerging markets, carry risks related to regulatory approvals, market adoption, and distribution challenges.
Inventory and cash flow management: Lower revenues relative to operating expenses partially offset improvements in working capital management, indicating potential cash flow pressures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future U.S. Study for ORMP-0801: Lifeward plans to initiate a new U.S. study for ORMP-0801, an advanced clinical-stage oral insulin candidate, which has the potential to improve patient safety and treatment adherence.
Upper Extremity Orthotic System Development: Lifeward intends to develop and launch a powered upper extremity orthotic system with AI capabilities to assist individuals with weakened or paralyzed arms, particularly stroke survivors. This platform is expected to expand Lifeward's leadership in robotic rehabilitation.
Reimbursement and Sales Structure Changes: The company expects positive effects from its restructured sales and distribution model, which combines direct sales efforts with external channel partnerships, to materialize in the coming quarters.
AlterG Sales Normalization: Lifeward anticipates AlterG sales to normalize in 2026 following a decline in 2025 due to distributor dynamics.
International Expansion: The company is accelerating efforts in Europe, with Germany as a primary test market, and expanding distribution into Mexico, Thailand, and the UAE through partnerships.
Next-Generation Products: Lifeward plans to launch a new version of Ultra G and a next-generation ReWalk system, as well as bring the upper body exoskeleton platform to market.
R&D Investment: The company plans to increase R&D investment in 2026 to advance new products to market, including the recently acquired powered upper body exoskeleton.
Cash Flow Positive Operations: Lifeward aims to achieve cash flow positive operations in the near future, supported by growth in its core MedTech business and improved operating expenses.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the status and alignment of the oral insulin technology with the company's commercial infrastructure?
A:The CEO stated that the specifics would be clearer post-acquisition closure. He emphasized his extensive experience in the metabolic space and highlighted the potential synergies between med tech and biotech. The company aims to transition to a decentralized approach, leveraging the innovation of oral insulin.
Q:How will the company leverage its current commercial infrastructure for the oral insulin product?
A:The CEO mentioned that the acquisition fully funds the clinical trials, allowing the company to focus on its core business. He also highlighted his experience in developing distribution networks and expressed confidence in the company's ability to commercialize the product when the opportunity arises.
Q:What is the timeline and regulatory process for the upper extremity robotic systems?
A:The CEO stated that the product might qualify as a 510(k) exempt product, which would lower barriers to entry. He confirmed the 18-24 month timeline and mentioned ongoing work to meet coding requirements. Clinical studies, if needed, would likely be small and focused on safety and efficacy.
Q:How does the company view its competitive advantage in the upper extremity robotic systems market?
A:The CEO avoided providing a direct answer, stating that more time is needed to assess the market. He mentioned plans to enter the market differently and emphasized the simplicity and efficacy of their product.
Q:How should investors view the company's strategy of diversifying into biotech and med tech?
A:The CEO explained that the company aims to become an innovation-driven organization with strong commercialization and reimbursement capabilities. He emphasized the benefits of a diversified portfolio and his extensive experience in payer and commercial contracts.
Q:What drove the company's higher-than-expected revenue and what should be expected in the future?
A:The CEO attributed the revenue growth to improved commercialization and reimbursement pathways. He mentioned ongoing efforts to maximize coverage and improve manufacturing processes, aiming for operational discipline and scalability.
Q:What is the current backlog for Medicare beneficiaries and the outlook for 2026?
A:The CEO acknowledged the record placements for Medicare beneficiaries but stated that the pipeline is not yet solidified due to expanding reimbursement coverage. He highlighted a 22% year-over-year growth in units and encouraged focus on unit expansion.
Q:Review of Unclear Management Responses
A:The CEO avoided directly answering the question about the company's competitive advantage in the upper extremity robotic systems market, stating that more time is needed to assess the market and emphasizing plans to enter differently.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Almog
Today
acquisition
adoption system
agreement Oramed
body exoskeleton
capital equipment
channel
close agreement
closing transaction
core
decrease
distributor order
dynamic
engineering
equipment sale
function
generation
impairment charge
insulin
liver
neuro rehabilitation
opportunity
payer engagement
platform
progress reimbursement
property
receipt
reimbursement coverage
risk hypoglycemia
sale efficiency
stroke survivor
structure
technology development
LFWD Transcript
Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call revealed a 14% revenue decline and flat exoskeleton sales, despite increased unit sales. Gross profit improved, but operating expenses and losses remain high. The Q&A section highlighted uncertainties in the company's market strategy and competitive advantage. Positive elements included narrowed net loss and reduced operating cash usage. However, weak financial performance and lack of clear competitive strategy outweigh these positives, leading to a negative sentiment.
Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call highlights operational efficiencies and a strong pipeline, but concerns arise due to increased operating expenses and cash constraints. The Q&A reveals optimism in partnerships and revenue growth, yet lacks clarity on strategic execution. Despite the positive outlook, uncertainties in Medicare reliance and AlterG sales decline temper enthusiasm. The neutral rating reflects mixed signals, with potential growth balanced by financial and operational challenges.
Lifeward Ltd. (LFWD) Q2 2025 Earnings Call Transcript
Unknown8-14
Despite some positive developments, such as operational efficiencies and Medicare revenue growth, the earnings report reflects mixed signals. Revenue decline, increased GAAP operating expenses due to goodwill impairment, and lack of clear guidance on margin improvements counterbalance the positives. The Q&A further highlights concerns about tariff impacts, unclear margin improvements, and lowered guidance despite expected revenue growth. These mixed signals suggest a neutral market reaction.
Lifeward Ltd. (LFWD) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call presents a mixed picture. Financial performance shows improvement in operating loss and gross margin, but revenue declined YoY. The Q&A reveals confidence in future growth, but uncertainties remain, especially with cash management and leadership transition risks. The lack of a shareholder return plan and ongoing financial challenges temper optimism. Positive aspects include improved margins and strategic partnerships, but these are offset by revenue decline and leadership risks, resulting in a neutral sentiment.
LFWD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
